Arcus Biosciences, Inc. (RCUS)

USD 15.17

(-5.66%)

Operating Expenses Summary of Arcus Biosciences, Inc.

Arcus Biosciences, Inc.'s latest annual operating expenses in 2023 was 457 Million USD , up 16.58% from previous year.
Arcus Biosciences, Inc.'s latest quarterly operating expenses in 2024 Q2 was 143 Million USD , up 1.42% from previous quarter.
Arcus Biosciences, Inc. reported a annual operating expenses of 392 Million USD in annual operating expenses 2022, up 19.28% from previous year.
Arcus Biosciences, Inc. reported a annual operating expenses of 328.63 Million USD in annual operating expenses 2021, up 62.89% from previous year.
Arcus Biosciences, Inc. reported a quarterly operating expenses of 141 Million USD for 2024 Q1, up 15.57% from previous quarter.
Arcus Biosciences, Inc. reported a quarterly operating expenses of 112 Million USD for 2023 Q2, up 0.9% from previous quarter.

Annual Operating Expenses Chart of Arcus Biosciences, Inc. (2023 - 2016)

Historical Annual Operating Expenses of Arcus Biosciences, Inc. (2023 - 2016)

Year	Operating Expenses	Operating Expenses Growth
2023	457 Million USD	16.58%
2022	392 Million USD	19.28%
2021	328.63 Million USD	62.89%
2020	201.75 Million USD	94.54%
2019	103.7 Million USD	64.07%
2018	63.21 Million USD	15.24%
2017	54.85 Million USD	201.69%
2016	18.18 Million USD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	143 Million USD	1.42%
2024 Q1	141 Million USD	15.57%
2023 Q2	112 Million USD	0.9%
2023 FY	457 Million USD	16.58%
2023 Q1	111 Million USD	2.78%
2023 Q3	112 Million USD	0.0%
2023 Q4	122 Million USD	8.93%
2022 Q2	95.74 Million USD	12.39%
2022 Q4	108 Million USD	4.88%
2022 FY	392 Million USD	19.28%
2022 Q1	85.18 Million USD	16.32%
2022 Q3	102.97 Million USD	7.56%
2021 Q1	82.2 Million USD	33.67%
2021 FY	328.63 Million USD	62.89%
2021 Q2	85.59 Million USD	4.12%
2021 Q4	73.23 Million USD	-16.4%
2021 Q3	87.59 Million USD	2.34%
2020 FY	201.75 Million USD	94.54%
2020 Q1	30.15 Million USD	10.53%
2020 Q2	47.12 Million USD	56.3%
2020 Q3	62.97 Million USD	33.64%
2020 Q4	61.49 Million USD	-2.35%
2019 Q4	27.27 Million USD	9.11%
2019 Q3	24.99 Million USD	-19.12%
2019 Q2	30.91 Million USD	50.61%
2019 Q1	20.52 Million USD	36.4%
2019 FY	103.7 Million USD	64.07%
2018 Q3	16.43 Million USD	-4.16%
2018 FY	63.21 Million USD	15.24%
2018 Q2	17.14 Million USD	17.61%
2018 Q1	14.58 Million USD	-0.09%
2018 Q4	15.04 Million USD	-8.46%
2017 Q1	7.3 Million USD	0.0%
2017 FY	54.85 Million USD	201.69%
2017 Q4	14.59 Million USD	-37.36%
2017 Q3	23.29 Million USD	141.07%
2017 Q2	9.66 Million USD	32.38%
2016 FY	18.18 Million USD	0.0%

Peer Operating Expenses Comparison of Arcus Biosciences, Inc.

Name	Operating Expenses	Operating Expenses Difference
ADC Therapeutics SA	233.01 Million USD	-96.125%
Alto Neuroscience, Inc.	37.8 Million USD	-1108.707%
Annovis Bio, Inc.	45.03 Million USD	-914.766%
Biohaven Pharmaceutical Holding Company Ltd.	436.05 Million USD	-4.804%
Ginkgo Bioworks Holdings, Inc.	1.1 Billion USD	58.769%
Nuvation Bio Inc.	99.82 Million USD	-357.815%
Nuvation Bio Inc.	99.82 Million USD	-357.815%
Theriva Biologics, Inc.	21.43 Million USD	-2032.425%
Zymeworks Inc.	196.76 Million USD	-132.263%